Latest News and Press Releases

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...

PharmAla launches new web portal for MDMA prescribers and appoints a new COO

ATMA CENA announce the expansion of its psychedelic therapy clinic network to 13 locations across Canada

Psycan discloses troubling statistics showing that Health Canada has begun to deny numerous doctor requests for MDMA and Psilocybin

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...

PharmAla incorporates a new entity in Australia to take advantage of tax incentives, and appoints Dr. Evan Lewis to its clinical advisory board.

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the...